Lumonus

About Lumonus

Lumonus is a healthcare technology company founded in 2024 and headquartered in Sydney, Australia, that is developing solutions to transform cancer care. The company's origins are rooted in the first-hand experiences of its team with the challenges faced by cancer care providers globally. The leadership team possesses over a century of combined clinical, operational, and technical experience from cancer centers worldwide.

The company's core offering is the Lumonus AI platform, a digital oncology system with AI-native clinical infrastructure designed to automate and orchestrate critical oncology workflows. This platform aims to enhance quality, speed up care delivery, and lessen the administrative load on healthcare professionals. Lumonus serves the US, Australian, and UK markets, providing its software and services to oncology clinics of all sizes.

Lumonus’s business model is centered on its twofold focus on user-centric software products and value-added services. The software, Lumonus AI, integrates with existing major EMR, OIS, and TPS systems, acting as an intelligent assistant. It automates tasks like clinical preparation, documentation, and treatment planning. The platform has two main product lines: Lumonus AI Physician and Lumonus AI Dosimetry. The Physician suite automates workflows for radiation oncologists, including diagnosis, AI-powered prescriptions, and outcomes tracking. The Dosimetry product transforms treatment planning with features for centralized management, automated planning, and web-enabled reviews. The company also offers services such as remote dosimetry, physics commissioning, and strategic consulting. They provide flexible implementation models where a client can use the software themselves or have Lumonus manage the planning transformation via technology-enabled services.

In March 2025, Lumonus raised $506K in a seed funding round. More recently, in November 2025, the company secured A$25 million in a Series B financing round led by Aviron Investment Management with participation from Oncology Ventures. This capital is intended to expand its U.S. commercial teams, further develop its product lines, and scale its clinical informatics work. The platform has already been used in over 280,000 cancer treatment prescriptions and has automated more than 75,000 treatment plans. A significant partnership was announced in September 2025 through a multi-year agreement with Smarter Radiation Oncology (SRO), a company incubated by Northwell Health. This collaboration integrates SRO's evidence-based treatment protocols into the Lumonus AI platform, providing clinicians with access to validated prescribing standards at the point of care.